Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,027 | -11,508 | -10,060 | -13,179 | -11,231 |
| Depreciation Amortization | 157 | 206 | 276 | 234 | 224 |
| Other Working Capital | 23 | 134 | -923 | -1,026 | -1,261 |
| Other Operating Activity | 1,665 | 3,767 | 1,159 | 1,201 | 1,146 |
| Operating Cash Flow | $-5,183 | $-7,401 | $-9,549 | $-12,769 | $-11,122 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,017 | -13 | -25 | -203 | -45 |
| Investing Cash Flow | $-3,017 | $-13 | $-25 | $-203 | $-45 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -29 | N/A | N/A | N/A |
| Common Stock Issued | 5,733 | 7,837 | 7,518 | 8,400 | 13,402 |
| Financing Cash Flow | $5,733 | $7,809 | $7,518 | $8,400 | $13,402 |
| Beginning Cash Position | 3,230 | 2,834 | 4,889 | 9,462 | 7,227 |
| End Cash Position | 762 | 3,230 | 2,834 | 4,889 | 9,462 |
| Net Cash Flow | $-2,467 | $396 | $-2,055 | $-4,572 | $2,234 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,183 | -7,401 | -9,549 | -12,769 | -11,122 |
| Capital Expenditure | -3,017 | -16 | -34 | -203 | -45 |
| Free Cash Flow | -8,200 | -7,417 | -9,583 | -12,972 | -11,167 |